Method AI, a medical technology innovator dedicated to advancing oncology outcomes, has secured $20 million in Series A funding to further develop its pioneering surgical ultrasound platform. Originating from Cleveland Clinic in 2021, Method AI was founded in response to challenges faced by leading robotic surgeons, who struggled with inadequate visualization of subsurface anatomy during complex surgical oncology procedures. The latest financing round, led by a private family office and featuring participation from Cleveland Clinic and the JobsOhio Growth Capital Fund, will accelerate the company’s mission to enhance surgical precision and patient results.
At the heart of Method AI’s approach is a novel technology that allows physicians to “see” beyond the organ’s surface—enabling real-time visualization of anatomy hidden from conventional surgical cameras. By constructing a 3D subsurface map and integrating it with an AI-generated surgical plan, the platform offers unprecedented guidance for surgeons during tumor removal procedures.
This innovation holds significant promise for improving cancer-free survival rates, as incomplete tumor removal remains a persistent challenge in oncology, with studies indicating that up to 40% of surgeries may leave residual cancerous tissue.
Method AI’s platform employs continuous 3D ultrasound imaging, paired with advanced algorithms and machine learning. This combination empowers physicians to track and respond to critical subsurface features throughout the duration of a procedure, adapting to the dynamic surgical environment.
In addition to improving patient outcomes, the technology is projected to reduce healthcare system costs by more than $1 billion annually by minimizing complications, avoiding repeat surgeries, and preserving organ function.
With support from its investment partners, Method AI is poised to transform the landscape of surgical oncology, making precise and complete tumor removal more achievable and delivering tangible benefits for both patients and healthcare providers.
KEY QUOTE:
“In complex oncology procedures, surgeons often have to remove tumors that are partially or completely embedded within the organ, making it extremely difficult to gauge the margins of the tumor during a live surgery. This incomplete view of the tumor and other critical anatomy leads to cancer left behind, unforeseen complications and loss of organ function. With the support of our investment partners, our technology can make the difference between completely removing a tumor or leaving part of it behind, which significantly impacts long-term patient outcomes.”
Doug Teany, Co-Founder and CEO of Method AI
